Evaluation of lung recovery after static administration of three different perfluorocarbons in pigs

BMC Clinical Pharmacology

Renaud Tissier²  Alain Berdeaux¹  Luc Darrasse⁵  Richard E Kerber⁴  Jean-Damien Ricard⁶  Daniel Isabey³  Xavier Maître⁵  Anis Ben Yahmed⁵  Rose-Marie Dubuisson⁵  Matthias Korn⁵  Bijan Ghaleh²  Aurélien Seemann²  Matthias Kohlhauer²  Fanny Lidouren²  Patrick Bruneval⁷  Ludovic De Rochefort⁵  Mourad Chenoune² 

[1] INSERM U955, Equipe 3, Créteil F-94010, France;Université Paris-Est, Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort F-94704, France;INSERM U955, Equipe 13, Créteil F-94010, France;Department of Internal Medicine, Division of Cardiovascular Medicine, University of Iowa Hospitals and Clinics, Iowa City IA 52242, US;IR4M (Imagerie par Résonance Magnétique Médicale et Multi-modalités), Univ Paris-Sud, CNRS, UMR8081, Orsay, France;AP-HP, Service de Réanimation Médico-chirurgicale, Hôpital Louis Mourier, F-92700 Colombes, France;INSERM U970, Paris F75015, France

关键词: Swine;    Macrophage;    Liquid ventilation;    Perfluorocarbon;   

Others  :  1084725
DOI  :  10.1186/2050-6511-15-53

 received in 2014-03-04, accepted in 2014-09-18,  发布年份 2014

【 摘 要 】

Background

The respiratory properties of perfluorocarbons (PFC) have been widely studied for liquid ventilation in humans and animals. Several PFC were tested but their tolerance may depend on the species. Here, the effects of a single administration of liquid PFC into pig lungs were assessed and compared. Three different PFC having distinct evaporative and spreading coefficient properties were evaluated (Perfluorooctyl bromide [PFOB], perfluorodecalin [PFD] and perfluoro-N-octane [PFOC]).

Methods

Pigs were anesthetized and submitted to mechanical ventilation. They randomly received an intra-tracheal administration of 15 ml/kg of either PFOB, PFD or PFOC with 12 h of mechanical ventilation before awakening and weaning from ventilation. A Control group was submitted to mechanical ventilation with no PFC administration. All animals were followed during 4 days after the initial PFC administration to investigate gas exchanges and clinical recovery. They were ultimately euthanized for histological analyses and assessment of PFC residual concentrations within the lungs using dual nuclei fluorine and hydrogen Magnetic Resonance Imaging (MRI). Sixteen animals were included (4/group).

Results

In the PFD group, animals tended to be hypoxemic after awakening. In PFOB and PFOC groups, blood gases were not significantly different from the Control group after awakening. The poor tolerance of PFD was likely related to a large amount of residual PFC, as observed using MRI in all lung samples (≈10% of lung volume). This percentage was lower in the PFOB group (≈1%) but remained significantly greater than in the Control group. In the PFOC group, the percentage of residual PFC was not significantly different from that of the Control group (≈0.1%). Histologically, the most striking feature was an alveolar infiltration with foam macrophages, especially in the groups treated by PFD or PFOB.

Conclusions

Of the three tested perfluorocarbons, PFOC offered the best tolerance in terms of lung function, gas exchanges and residuum in the lung. PFOC was rapidly cleared from the lungs and virtually disappeared after 4 days whereas PFOB persisted at significant levels and led to foam macrophage infiltration. PFOC could be relevant for short term total liquid ventilation with a rapid weaning.

【 授权许可】

   
2014 Chenoune et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Hirschl RB, Pranikoff T, Gauger P, Schreiner RJ, Dechert R, Bartlett RH: Liquid ventilation in adults, children, and full-term neonates. Lancet 1995, 346:1201-1202.
• [2]Leach CL, Greenspan JS, Rubenstein SD, Shaffer TH, Wolfson MR, Jackson JC, De Lemos R, Fuhrman BP: Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent study group. N Engl J Med 1996, 335:761-767.
• [3]Avoine O, Bosse D, Beaudry B, Beaulieu A, Albadine R, Praud JP, Robert R, Micheau P, Walti H: Total liquid ventilation efficacy in an ovine model of severe meconium aspiration syndrome. Crit Care Med 2011, 39:1097-1103.
• [4]Clark LC Jr, Gollan F: Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 1966, 152:1755-1756.
• [5]Wolfson MR, Shaffer TH: Pulmonary applications of perfluorochemical liquids: ventilation and beyond. Paediatr Respir Rev 2005, 6:117-127.
• [6]Shaffer TH, Forman DL, Wolfson MR: Physiological effects of ventilation with liquid fluorocarbon at controlled temperatures. Undersea Biomed Res 1984, 11:287-298.
• [7]Richman PS, Wolfson MR, Shaffer TH: Lung lavage with oxygenated perfluorochemical liquid in acute lung injury. Crit Care Med 1993, 21:768-774.
• [8]Tissier R, Hamanaka K, Kuno A, Parker JC, Cohen MV, Downey JM: Total liquid ventilation provides ultra-fast cardioprotective cooling. J Am Coll Cardiol 2007, 49:601-605.
• [9]Staffey KS, Dendi R, Brooks LA, Pretorius AM, Ackermann LW, Zamba KD, Dickson E, Kerber RE: Liquid ventilation with perfluorocarbons facilitates resumption of spontaneous circulation in a swine cardiac arrest model. Resuscitation 2008, 78:77-84.
• [10]Jeng MJ, Yang SS, Hwang B, Wolfson MR, Shaffer TH: Effects of perfluorochemical evaporative properties on oxygenation during partial liquid ventilation. Pediatr Int 2006, 48:608-615.
• [11]Hirschl RB, Pranikoff T, Wise C, Overbeck MC, Gauger P, Schreiner RJ, Dechert R, Bartlett RH: Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome. JAMA 1996, 275:383-389.
• [12]Hirschl RB, Croce M, Gore D, Wiedemann H, Davis K, Zwischenberger J, Bartlett RH: Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome. Am J Respir Crit Care Med 2002, 165:781-787.
• [13]Miller TF, Milestone B, Stern R, Shaffer TH, Wolfson MR: Effects of perfluorochemical distribution and elimination dynamics on cardiopulmonary function. J Appl Physiol 2001, 90:839-849.
• [14]Kacmarek RM, Wiedemann HP, Lavin PT, Wedel MK, Tutuncu AS, Slutsky AS: Partial liquid ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2006, 173:882-889.
• [15]Chenoune M, Lidouren F, Adam C, Pons S, Darbera L, Bruneval P, Ghaleh B, Zini R, Dubois-Rande JL, Carli P, Vivien B, Ricard JD, Berdeaux A, Tissier R: Ultrafast and whole-body cooling with total liquid ventilation induces favorable neurological and cardiac outcomes after cardiac arrest in rabbits. Circulation 2011, 124:901-911.
• [16]Chenoune M, Lidouren F, Ghaleh B, Couvreur N, Dubois-Rande JL, Berdeaux A, Tissier R: Rapid cooling of the heart with total liquid ventilation prevents transmural myocardial infarction following prolonged ischemia in rabbits. Resuscitation 2010, 81:359-362.
• [17]Tissier R, Chenoune M, Ghaleh B, Cohen MV, Downey JM, Berdeaux A: The small chill: mild hypothermia for cardioprotection? Cardiovasc Res 2010, 88:406-414.
• [18]Tissier R, Couvreur N, Ghaleh B, Bruneval P, Lidouren F, Morin D, Zini R, Bize A, Chenoune M, Belair MF, Mandet C, Douheret M, Dubois-Rande JL, Parker JC, Cohen MV, Downey JM, Berdeaux A: Rapid cooling preserves the ischaemic myocardium against mitochondrial damage and left ventricular dysfunction. Cardiovasc Res 2009, 83:345-353.
• [19]Degraeuwe PL, Vos GD, Blanco CE: Perfluorochemical liquid ventilation: from the animal laboratory to the intensive care unit. Int J Artif Organs 1995, 18:674-683.
• [20]Fuhrman BP, Paczan PR, DeFrancisis M: Perfluorocarbon-associated gas exchange. Crit Care Med 1991, 19:712-722.
• [21]Riter HG, Brooks LA, Pretorius AM, Ackermann LW, Kerber RE: Intra-arrest hypothermia: both cold liquid ventilation with perfluorocarbons and cold intravenous saline rapidly achieve hypothermia, but only cold liquid ventilation improves resumption of spontaneous circulation. Resuscitation 2009, 80:561-566.
• [22]Darbera L, Chenoune M, Lidouren F, Kohlhauer M, Adam C, Bruneval P, Ghaleh B, Dubois-Rande JL, Carli P, Vivien B, Ricard JD, Berdeaux A, Tissier R: Hypothermic liquid ventilation prevents early hemodynamic dysfunction and cardiovascular mortality after coronary artery occlusion complicated by cardiac arrest in rabbits. Crit Care Med 2013, 41:e457-e465.
• [23]Diaz-Lopez R, Tsapis N, Fattal E: Liquid perfluorocarbons as contrast agents for ultrasonography and (19) F-MRI. Pharm Res 2010, 27:1-16.
• [24]Keupp J, Rahmer J, Grasslin I, Mazurkewitz PC, Schaeffter T, Lanza GM, Wickline SA, Caruthers SD: Simultaneous dual-nuclei imaging for motion corrected detection and quantification of 19 F imaging agents. Magn Reson Med 2011, 66:1116-1122.
• [25]Ruiz-Cabello J, Barnett BP, Bottomley PA, Bulte JW: Fluorine (19 F) MRS and MRI in biomedicine. NMR Biomed 2011, 24:114-129.
• [26]Reickert C, Pranikoff T, Overbeck M, Kazerooni E, Massey K, Bartlett R, Hirschl R: The pulmonary and systemic distribution and elimination of perflubron from adult patients treated with partial liquid ventilation. Chest 2001, 119:515-522.
• [27]Weers J: A physicochemical evaluation of perfluorochemicals for oxygen transport applications. J Fluorine Chem 1993, 64:73-93.
• [28]Dias A, Caço A, Coutino J, Santos L, Pipfeiro M, Vega L, Costa Gomes M, IM M: Thermodynamic properties of perfluoro-n-octane. Fluid Phase Equilib 2004, 225:39-47.
• [29]Faithfull N, Weers J: Partial Liquid Breathing of Fluorocarbons. United States: Alliance Pharmaceutical Corp (San Diego, CA); 2001. [US Patent. 6,289,892]
• [30]Meinert H, Roy T: Semifluorinated alkanes–a new class of compounds with outstanding properties for use in ophthalmology. Eur J Ophthalmol 2000, 10:189-197.
• [31]Ricard JD, Dreyfuss D, Laissy JP, Saumon G: Dose–response effect of perfluorocarbon administration on lung microvascular permeability in rats. Am J Respir Crit Care Med 2003, 168:1378-1382.
• [32]Ricard JD, Iserin F, Dreyfuss D, Saumon G: Perflubron dosing affects ventilator-induced lung injury in rats with previous lung injury. Crit Care Med 2007, 35:561-567.
• [33]Nanney L, Fink LM, Virmani R: Perfluorochemicals. Morphologic changes in infused liver, spleen, lung, and kidney of rabbits. Arch Pathol Lab Med 1984, 108:631-637.
• [34]Flaim SF: Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Substit Immobil Biotechnol 1994, 22:1043-1054.
• [35]Kaneda MM, Caruthers S, Lanza GM, Wickline SA: Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng 2009, 37:1922-1933.
• [36]Mattrey RF: The potential role of perfluorochemicals (PFCs) in diagnostic imaging. Artif Cells Blood Substit Immobil Biotechnol 1994, 22:295-313.
• [37]McGoron AJ, Pratt R, Zhang J, Shiferaw Y, Thomas S, Millard R: Perfluorocarbon distribution to liver, lung and spleen of emulsions of perfluorotributylamine (FTBA) in pigs and rats and perfluorooctyl bromide (PFOB) in rats and dogs by 19 F NMR spectroscopy. Artif Cells Blood Substit Immobil Biotechnol 1994, 22:1243-1250.